Medibact GuidesShop at Medibact

Stacking Module

GHRP-2 Stacking Module

GHRP-2 is an older-generation ghrelin-receptor secretagogue, and its stacking picture is defined by the trade-off that made Ipamorelin displace it: more reported potency on GH release, but less selectivity, with cortisol and prolactin effects attributed to it.

GHRP-2 Guide at MedibactGHRP-2 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking GHRP-2

  • GHRP-2 acts at GHS-R1a. Its complementary partner is a GHRH analog, not another secretagogue.
  • It is reported as more potent than Ipamorelin on GH release and less selective — the reason to choose it, and the reason to be cautious, are the same fact.
  • Reported cortisol and prolactin effects are the practical differentiator from Ipamorelin and the usual reason it is not the default choice.
  • No controlled trial has studied GHRP-2 combined with anything.

Combinations in detail

GHRP-2 + CJC-1295

Secretagogue + GHRH analog
Why it is proposed
The two-pathway construction with the more potent secretagogue. Both pathways converge on GH release from different receptors.
What is reported in practice
Reported drawn together, fasted, commonly at bedtime with no-DAC CJC-1295.
Cautions specific to this combination
GHRP-2's reported cortisol and prolactin effects are the cost of its potency; sources describe this as the main reason to prefer Ipamorelin instead.

GHRP-2 + Sermorelin

Secretagogue + GHRH analog (short-acting)
Why it is proposed
Same pairing using the GHRH analog closest to native GHRH.
What is reported in practice
Reported as an alternate GHRH pairing; Sermorelin's short half-life makes timing consequential.
Cautions specific to this combination
Same selectivity trade-off as above.

GHRP-2 + Tesamorelin

Secretagogue + approved GHRH analog
Why it is proposed
Pairs the potent secretagogue with the stabilized, approved GHRH analog.
What is reported in practice
Reported in secretagogue discussion as a GHRH alternative.
Cautions specific to this combination
Tesamorelin's label carries glucose-tolerance monitoring guidance; adding a potent secretagogue is not neutral to that. Clinician involvement is the appropriate route.

What to avoid, and why

  • Pairing two ghrelin-receptor secretagogues (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) is the same redundancy on the other pathway — same receptor, same downstream pulse. The coherent construction takes one GHRH analog and one secretagogue, not two of either.
  • Combining GHRP-2 with Ipamorelin, GHRP-6 or Hexarelin — same receptor.
  • Choosing GHRP-2 for potency and then also expecting Ipamorelin's selectivity profile; they are opposite ends of one trade-off.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.